Ingrid Belac Lovasić

Ingrid Belac Lovasić

Auto-generated profile, based on publicly available information

Ingrid Belac Lovasić

School of Medicine University of Rijeka, Rijeka, Croatia

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2010 in Toxicologic Pathology
Verified
Journal Article
Open access
Aleksandra FucicAleksandra Fucic
Aleksandra Fucic
MGMarija Gamulin
Marija Gamulin
ZFZeljko Ferencic
Zeljko Ferencic
DRDinko Stancic Rokotov
Dinko Stancic Rokotov
JKJelena Katic
Jelena Katic
DMDomenico Franco Merlo
Domenico Franco Merlo
Lung cancer is a dominant cause of cancer mortality. The etiology of lung cancer is mainly related to cigarette smoking, airborne genotoxic carcinogens, and arsenic, but its sex-specific incidence suggests that other mechanisms, such as hormones, may also be involved in the process of carcinogenesis. A number of agents commonly present in the living environment can have dual biological effects: not only are they genotoxic / carcinogenic, but they are also hormonally active as xenoestrogens. This dualism may explain sex-specific differences reported in both types and incidence of lung cancer. In a novel approach to investigate the complexity of lung cancer, etiology, including systems biology, will be used as a tool for a simultaneous interpretation of measurable environmental and biological parameters. Using this approach, the etiology of human lung cancer can be more thoroughly investigated using the available data from oncology and environmental health. The information gained could be applied in the introduction of preventive measures, in personalized medicine, and in more relevant legislation, which should be adjusted to reflect the current knowledge on the complex environmental interactions underlying this life-threatening disease.

1 February 2017 in The Breast
Verified
Journal Article
Closed access
LBLidija Bošković
Lidija Bošković
MGMaja Gašparić
Maja Gašparić
MPMarija Petković
Marija Petković
DGDamir Gugić
Damir Gugić
ILIngrid Belac Lovasić
Ingrid Belac Lovasić
EVEduard Vrdoljak
Eduard Vrdoljak

28 June 2023 in Cancers
Verified
Journal Article
Open access
PDF file
DČDora Čerina
Dora Čerina
KKKristina Krpina
Kristina Krpina
MJMarko Jakopovic
Marko Jakopovic
NPNatalija Dedić Plavetić
Natalija Dedić Plavetić
FSFran Seiwerth
Fran Seiwerth
EVEduard Vrdoljak
Eduard Vrdoljak
Non–small cell lung cancer (NSCLC) has become the best example of precision oncology’s impact on outcomes in everyday clinical practice, significantly changing the expectations of all stakeholders, including medical professionals, society, and most importantly, patients. Consequently, the implementation of the precision oncology concept in medical systems, in order to achieve optimal and proven curative effects in NSCLC, is imperative. In this study, we investigated the development, challenges, and results associated with the implementation of precision oncology in NSCLC on a national level in Croatia. We conducted a multicenter, retrospective, cross-sectional analysis on the total population of Croatian patients with metastatic lung cancer, on whose tumors specimen comprehensive genomic profiling (CGP) testing was performed during 2020 and 2021. A total of 48 patients were included in the study. CGP revealed clinically relevant genomic alterations (CRGA) in 37 patients (79%), with a median of 2 (IQR 1–3) CRGA per patient. From the panel of recommended tests, KRAS, MET, and EGFR were the most common alterations, detected in 16 (34%), 5 (11%), and 3 (6%) patients, respectively. CGP revealed additional targetable mutations in 29 (60%) patients who would not have been tested (and consequently, whose mutations would not have been detected) according to the existing everyday standard of practice in Croatia. The tumor mutational burden was reported as high (≥10 Muts/Mb) in 19 patients (40%). CGP analysis reported some kind of targeted therapy for 34 patients (72%). CGP revealed other potentially targetable mutations, and it also determined TMB to be high in a significant number of patients. In conclusion, when possible, CGP should be used as an upfront backbone diagnostic and treatment-oriented work-up in patients with NSCLC.

1 September 2018 in Lijecnicki Vjesnik
Verified
Journal Article
Open access
EVEduard Vrdoljak
Eduard Vrdoljak
SPStjepko Pleština
Stjepko Pleština
TOTomislav Omrčen
Tomislav Omrčen
AJAntonio Juretić
Antonio Juretić
IBIngrid Belac-Lovasić
Ingrid Belac-Lovasić
KOKlinika Za Onkologiju
Klinika Za Onkologiju

Verified
Journal Article
Open access
PDF file
DČDora Čerina
Dora Čerina
VMVišnja Matković
Višnja Matković
KKKristina Katić
Kristina Katić
ILIngrid Belac Lovasić
Ingrid Belac Lovasić
RŠRobert Šeparović
Robert Šeparović
EVEduard Vrdoljak
Eduard Vrdoljak
Today, in the era of precision medicine, the determination of genomic instability or other potentially targetable mutations, along with BRCA 1 and BRCA 2, is a crucial component of the diagnosis and treatment management of advanced ovarian cancer. Advanced technologies such as next-generation sequencing (NGS) have enabled comprehensive genomic profiling (CGP) analysis to become more feasible for routine use in daily clinical work. Here, we present the results for the first two years of an analysis of patients with advanced ovarian cancer on a national level. The aim was to establish the position of CGP in the daily clinical practice of treating ovarian cancer. We performed a multicenter, retrospective, cross-sectional analysis on the total population of Croatian patients who were newly diagnosed with locally advanced or metastatic ovarian cancer or whose initial disease had progressed from 1 January 2020 to 1 December 2021, and whose tumors underwent CGP analysis. All 86 patients (100%) analyzed with CGP had at least one genomic alteration (GA). The median LOH was 14.6 (IQR 6.8–21.7), with 35 patients (41%) having an LOH ≥ 16. We found BRCA-positive status in 22 patients (26%). Conventional testing, which detects only BRCA mutations, would have opted for therapy with PARP inhibitors in 22 (26%) of our patients. However, CGP revealed the need for PARP inhibitors in 35 patients (41%). The results identified a significantly higher number of women who would achieve a possible benefit from targeted therapy. Hence, we believe that CGP should be a backbone diagnostic tool in the management of ovarian cancer.

20 June 2020 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
AMAna Majić
Ana Majić
BMBranka Petrić Miše
Branka Petrić Miše
VMVišnja Matković
Višnja Matković
ILIngrid Belac Lovasić
Ingrid Belac Lovasić
KKKristina Katić
Kristina Katić
EVEduard Vrdoljak
Eduard Vrdoljak
Our objective was to assess the safety and efficacy of olaparib in maintenance therapy of BRCA 1-2 mutated, platinum-sensitive, recurrent ovarian carcinoma after the partial or complete response to the second or further lines platinum-based chemotherapy in a real-world setting. We performed a multicenter, real-world observational population-based cohort study on the whole population of Croatian patients initiated to olaparib maintenance therapy between 2016 and 2020. The primary endpoints were progression-free survival and the discontinuation of treatment because of adverse events. We enrolled the total population of 69 patients with the median (interquartile range; IQR) age of 53 (48–59), 56 (81%) of them with BRCA1 mutation. The median (IQR) follow-up was 16 (9–25) months. Treatment had to be discontinued because of toxicity in 2 (3%) and temporarily interrupted in 14 (20%), while dose was reduced because of toxicity in 18 (26%) of patients. Toxicity of any grade was observed in 61 (88%) patients and toxicity of grade 3 or 4 in 12 (17%). Median progression-free survival was 21 (95% CI 16-not calculable) months from the introduction of olaparib, and the median overall survival was not reached. Our study confirmed efficacy and safety of olaparib as the maintenance therapy of BRCA 1-2 mutated, platinum-sensitive, recurrent ovarian carcinoma. We observed the real-world efficacy and safety comparable to those observed in the randomized controlled trials. We found the interesting observation of better efficacy of 300 mg tablets, compared to 400 mg capsules, an issue that should be addressed on much larger real-world populations.